Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGBL2 | Q5U5Z8 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | ERN1 | O75460 | 1/20 | 0.31 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.30 |
| ▸ | TNKS | O95271 | 1/20 | 0.30 |
| ▸ | PARP1 | P09874 | 1/20 | 0.30 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17224965 | 0.81 | HTT (0.31) | — | |
| SCHEMBL4673064 | 0.76 | AGBL2 (0.37) | AGBL2 | |
| SCHEMBL2172358 | 0.76 | AGBL2 (0.37) | AGBL2 | |
| SCHEMBL14738285 | 0.76 | AGBL2 (0.37) | AGBL2MAPK1ADORA2A | |
| SCHEMBL23695333 | 0.72 | AGBL2 (0.39) | AGBL2 | |
| SCHEMBL9951955 | 0.72 | AGBL2 (0.39) | AGBL2 | |
| SCHEMBL29475252 | 0.72 | AGBL2 (0.39) | AGBL2 | |
| SCHEMBL134813 | 0.72 | AGBL2 (0.43) | AGBL2MAPK1ADORA2A | |
| SCHEMBL29941432 | 0.72 | AGBL2 (0.43) | AGBL2MAPK1ADORA2A | |
| SCHEMBL357848 | 0.72 | AGBL2 (0.39) | AGBL2ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4514794-A1 | FGFR2 INHIBITOR COMPOUNDS | Eli Lilly and Company (US) | 2025-03-05 | — | — | EP | disclosed |
| WO-2023212535-A1 | FGFR2 INHIBITOR COMPOUNDS | ELI LILLY AND COMPANY (US) | 2023-11-02 | — | — | WO | disclosed |
| EP-3983073-A1 | SUBSTITUTED PYRAZOLO[4,3-B]PYRIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | Janssen Pharmaceutica NV (BE) | 2022-04-20 | — | — | EP | disclosed |
| WO-2020249791-A1 | SUBSTITUTED PYRAZOLO[4,3-b]PYRIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2020-12-17 | — | — | WO | disclosed |
| EP-2346859-A1 | HETEROCYCLIC JAK KINASE INHIBITORS | AstraZeneca AB (SE) | 2011-07-27 | — | — | EP | disclosed |
| EP-2288602-A1 | TRICYCLIC 2,4-DIAMIN0-L,3,5-TRIAZINE DERIVATIVES USEFUL FOR THE TREATMENT OF CANCER AND MYELOPROLIFERATIVE DISORDERS | AstraZeneca AB (SE) | 2011-03-02 | — | — | EP | disclosed |
| WO-2010038060-A1 | HETEROCYCLIC JAK KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2010-04-08 | — | — | WO | disclosed |
| WO-2010020810-A1 | 2-(IMIDAZ0LYLAMIN0)-PYRIDINE DERIVATIVES AND THEIR USE AS JAK KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2010-02-25 | — | — | WO | disclosed |
| WO-2009150462-A1 | TRICYCLIC 2,4-DIAMIN0-L,3,5-TRIAZINE DERIVATIVES USEFUL FOR THE TREATMENT OF CANCER AND MYELOPROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2009-12-17 | — | — | WO | disclosed |
| WO-2009016410-A2 | CHEMICAL COMPOUNDS 831 | ASTRAZENECA AB (SE) | 2009-02-05 | — | — | WO | disclosed |
| WO-2008132502-A1 | PYRAZOLYL-AMINO-SUBSTITUTED PYRIMIDINES AND THEIR USE FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2008-11-06 | — | — | WO | disclosed |